相关实验视频

Updated: Jun 26, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

在异常性肺高血压中进行右心导管治疗:一个全面的必要性

Srilakshmi M Adhyapak¹, Abhilash Konda¹, Thirumal K T¹

¹Department of Cardiology, St. John's medical College Hospital, Bangalore 560034, India.

Current problems in cardiology

|May 16, 2024

概括

右心腔导管是诊断肺高血压的黄金标准,但需要专业知识. 本指南详细介绍了该程序和常见的陷,以确保准确的诊断并避免并发症.

科学领域:

心脏病学心脏病学
肺部医学肺部医学
医疗程序医疗程序

背景情况:

肺高血压的诊断严重依赖于侵入性手术.
右心脏导管 (RHC) 是诊断肺高血压的既定黄金标准.
准确的RHC解释对于有效的患者管理至关重要.

研究的目的:

为诊断肺高血压提供RHC程序的全面概述.
识别和解释与RHC相关的常见技术陷.
通过改善程序理解,提高肺高血压诊断的准确性.

主要方法:

详细描述了右心脏导管技术.
分析过程中的潜在并发症和错误来源.
重点血液动力学参数的审查及其在肺高血压中的解释.

主要成果:

虽然RHC是最终的,但需要显著的操作员技能.
错误的技术可能导致误解肺高血压的严重程度.
意识到程序陷对于诊断完整性至关重要.

结论:

掌握RHC技术对于可靠的肺高血压诊断至关重要.
了解和避免常见的陷可以提高诊断的准确性.
本综述作为临床医生执行RHC的肺高血压的指南.

关键词:

心脏输出的心脏输出.在毛细血管前高血压.肺高血压是一种肺高血压."天"的Ganz导管导管

更多相关视频

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model

Published on: November 11, 2022

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...